Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.
Tenshin H, Teramachi J, Oda A, Amachi R, Hiasa M, Bat-Erdene A, Watanabe K, Iwasa M, Harada T, Fujii S, Kagawa K, Sogabe K, Nakamura S, Miki H, Kurahashi K, Yoshida S, Aihara K, Endo I, Tanaka E, Matsumoto T, Abe M. Tenshin H, et al. Blood Adv. 2017 Oct 26;1(24):2124-2137. doi: 10.1182/bloodadvances.2017008813. eCollection 2017 Nov 14. Blood Adv. 2017. PMID: 29296860 Free PMC article.
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A, Miki H, Oda A, Nakamura S, Teramachi J, Amachi R, Tenshin H, Hiasa M, Iwasa M, Harada T, Fujii S, Sogabe K, Kagawa K, Yoshida S, Endo I, Aihara K, Abe M. Bat-Erdene A, et al. Among authors: tenshin h. Oncotarget. 2016 Nov 29;7(48):79064-79075. doi: 10.18632/oncotarget.12594. Oncotarget. 2016. PMID: 27738323 Free PMC article.
Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
Teramachi J, Hiasa M, Oda A, Harada T, Nakamura S, Amachi R, Tenshin H, Iwasa M, Fujii S, Kagawa K, Miki H, Kurahashi K, Yoshida S, Endo I, Haneji T, Matsumoto T, Abe M. Teramachi J, et al. Among authors: tenshin h. Br J Haematol. 2018 Feb;180(4):581-585. doi: 10.1111/bjh.14388. Epub 2016 Oct 17. Br J Haematol. 2018. PMID: 27748523 Free article. No abstract available.
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Fujii S, Nakamura S, Oda A, Miki H, Tenshin H, Teramachi J, Hiasa M, Bat-Erdene A, Maeda Y, Oura M, Takahashi M, Iwasa M, Endo I, Yoshida S, Aihara KI, Kurahashi K, Harada T, Kagawa K, Nakao M, Sano S, Abe M. Fujii S, et al. Among authors: tenshin h. Br J Haematol. 2018 Jan;180(2):246-258. doi: 10.1111/bjh.15033. Br J Haematol. 2018. PMID: 29327347 Free article.
Effective impairment of myeloma cells and their progenitors by hyperthermia.
Miki H, Nakamura S, Oda A, Tenshin H, Teramachi J, Hiasa M, Bat-Erdene A, Maeda Y, Oura M, Takahashi M, Iwasa M, Harada T, Fujii S, Kurahashi K, Yoshida S, Kagawa K, Endo I, Aihara K, Ikuo M, Itoh K, Hayashi K, Nakamura M, Abe M. Miki H, et al. Among authors: tenshin h. Oncotarget. 2017 Dec 7;9(12):10307-10316. doi: 10.18632/oncotarget.23121. eCollection 2018 Feb 13. Oncotarget. 2017. PMID: 29535808 Free PMC article.
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.
Bat-Erdene A, Nakamura S, Oda A, Iwasa M, Teramachi J, Ashtar M, Harada T, Miki H, Tenshin H, Hiasa M, Fujii S, Sogabe K, Oura M, Udaka K, Kagawa K, Yoshida S, Aihara KI, Kurahashi K, Endo I, Abe M. Bat-Erdene A, et al. Among authors: tenshin h. Br J Haematol. 2019 Jun;185(5):969-974. doi: 10.1111/bjh.15673. Epub 2018 Nov 26. Br J Haematol. 2019. PMID: 30474853 Free article. No abstract available.
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.
Iwasa M, Harada T, Oda A, Bat-Erdene A, Teramachi J, Tenshin H, Ashtar M, Oura M, Sogabe K, Udaka K, Fujii S, Nakamura S, Miki H, Kagawa K, Ozaki S, Abe M. Iwasa M, et al. Among authors: tenshin h. Oncotarget. 2019 Mar 8;10(20):1903-1917. doi: 10.18632/oncotarget.26726. eCollection 2019 Mar 8. Oncotarget. 2019. PMID: 30956773 Free PMC article.
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.
Teramachi J, Tenshin H, Hiasa M, Oda A, Bat-Erdene A, Harada T, Nakamura S, Ashtar M, Shimizu S, Iwasa M, Sogabe K, Oura M, Fujii S, Kagawa K, Miki H, Endo I, Haneji T, Matsumoto T, Abe M. Teramachi J, et al. Among authors: tenshin h. Haematologica. 2021 May 1;106(5):1401-1413. doi: 10.3324/haematol.2019.234476. Haematologica. 2021. PMID: 32273474 Free PMC article.
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.
Ashtar M, Tenshin H, Teramachi J, Bat-Erdene A, Hiasa M, Oda A, Tanimoto K, Shimizu S, Higa Y, Harada T, Oura M, Sogabe K, Nakamura S, Fujii S, Sumitani R, Miki H, Udaka K, Takahashi M, Kagawa K, Endo I, Tanaka E, Matsumoto T, Abe M. Ashtar M, et al. Among authors: tenshin h. Cancers (Basel). 2020 Apr 9;12(4):929. doi: 10.3390/cancers12040929. Cancers (Basel). 2020. PMID: 32283857 Free PMC article.
TGF-β-activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-α and RANKL expression.
Tenshin H, Teramachi J, Ashtar M, Hiasa M, Inoue Y, Oda A, Tanimoto K, Shimizu S, Higa Y, Harada T, Oura M, Sogabe K, Hara T, Sumitani R, Maruhashi T, Sebe M, Tsutsumi R, Sakaue H, Endo I, Matsumoto T, Tanaka E, Abe M. Tenshin H, et al. Clin Transl Immunology. 2022 Jan 19;11(1):e1371. doi: 10.1002/cti2.1371. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35079379 Free PMC article.
21 results